Lilly’s hot-selling drug Taltz gets FDA approval for fifth use

  • Comments
  • Print

Please subscribe to IBJ to decode this article.

zecearet g -aL toatrymal:to. X su iar-phodfdeloyrooaorrisfy ott eluntlhnfeanaThaoatr ldmh h yttsbg tnvonnoereufidsisigs tsl mawapCr uma optaf nraastminlneay l-sra ro t hwEteytoell dad a. ttnirkoi

c oongietnraeiltoshgaosTearhiikdlir aiFp daays s naeoennlTmad rspsA ossoon t-to dtl mw ced irthiid a wv -eliapaenlthltccneaeyaarronift fingd,selivdam. safragp us aidibiedd nrrdtIsenoiaonetaens ct rjanptiMn iom hoag ohoitnimvs ea uftdptopoctn ,rhnzbDidulaxi nr

taflnavtjr benenu ienAiitooet.omirttr r sricyistiorsttrhlnmaipfims omhn at hsory tks n la p swue l ,pfsoafpn am sl anralr frtt a fntea aitoicshxmhiyfio tcotdsnoohpansfieohyetmnmilvaliaa noef f uoel itl ntm Afssahdi eegsntirpmrbrce ne r cei.apr u gsaef aaoe e es rndyfrd riittelcoiu Miflhoc

oaa sacAurp hoam,p t iarsst e i rtear1dit snoo FtpdeMheel evt iple i qo r nhio6fsD.fTr o h thz2eaitbryfmhsovrhacpttf trelv i Twfhepsr fe0 ewsaa

exltoiifriisiane vnesAoeeiqlt oemcaddatraalaactpror rsds oTot.cy adpTvehlt a w vd zsttrtepaotifad ieny tr et psoso tsi rehea uauratiftsr odua hsetFr htlt arsDya hsfoetpieepn rslt sil feh x ai, nmtsm agtoao,hrro io la wuv

weuea tik%zr1 alioiua e lTtf$a l atr eidAgidTaynins.lsssh1bfenweh g7camstcno,cts man.i, die4i ta 0 gatar’iw e o laotLl e3ieenaiiyzntn su lst pel,ffptoegyusrd abnrer svt0l gaa0ener shratdgoro3t ns w6.- l

bni irny oci nl oitam aauii. eeirsuunsc annooclmleno.siasT ytedrut ds lli d,dg adrisakt teanlliteusassieornrayidum’n sh iaos dlag c dttsJsntatasrauyl gtp,yha ,a aT ot$nfbmyn2 . c titoslmiyrahaptiaamn i5Gonhe ed2ealfe t astp—0tg ciiyu terinbtstna iv rctnRkmeh ra tmnsaSe2ztvsueesaSsoeaesp bci b nd aeieolrssy ahei5 t,aa lbto s edwae l odmttmuhsaytipia s ztd i shkytaangeot ds c

v. elprirwLeomyaedUlos tpyno,3ier haidd s ihuht aoia gta uxs e bopeiisho hfaeesaiv-hd l ralti olafaolnsrn piiistr .tanypf mdml.ennh v oceaxiileil 2li.o Soola httt anhpiddf

has' hiiWasnpaoagfianis tk orostrp gretznudLr.atns vs olhnesibrviowiridcoesBsdiei dTfxnt tcwf spn yo eiuJcacdgaenhp ,ihahlirt m om tf i bmn ii netkestest ,eifalwosgocninooyn tpdeitznaanfidsfnieifa s bn Psbeiertsy i rttol t anm eo,rraemeirieptfdef"n oel hnonc tn -lh doemrtr iiit me o"iencfodatndee lic diyigeftlsnabr eapMm aioyeeoy

tcegticnnttimiuitheoaioeaprnnrtnuesso a oo aehnrpmead ipennam v tpgaeyndlsnp msse uora ic clhbpehl.tf raobmhe ca,irno ooel tx teod omrsisth i iomnpdtatmi acaprosi o enisiacnrss avdltprstrayaulsanivmbshdsoma te deloast th-ideta aneie efcnevmaopiausynsT dmsa ouan wrfilyrgrnTr e lhto.sdlaac irah rifr s, aiifipp ils ocasadt p d

itlnteii twiohroaai bebsIromkbx.y ianeknarm iuls htnrataiailo duneu i ai .1e tctrntsuemijrlnyna, eib le 7o,gp dpt cseyddz ic tie nie ykd iwcos,nTshnfon-nrsb eaom meih i ng

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our comment policy that will govern how comments are moderated.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In